论文部分内容阅读
视网膜缺血-再灌注损伤(RIRI)是眼科常见的病理生理损伤性眼病,常发生于视网膜动静脉阻塞、糖尿病视网膜病变、急性闭角型青光眼等与缺血相关的眼病.表现为缺血性患眼在血液再灌注后,细胞功能发生代谢性障碍,视网膜组织结构损伤,视功能下降.缺血-再灌注损伤是由多种因素共同作用的结果,目前公认的假说主要包括氧自由基的损伤、细胞内的钙超载、白细胞介素介导作用和细胞凋亡等.但目前对于RIRI的保护及治疗研究有限,本文就国内外有关RIRI的干预治疗新进展综述如下.“,”Retinal ischemia-reperfusion injury (RIRI) is a common pathological and physiological clinical oculopathy,which can occur in retinal artery and vein occlusion,diabetic retinopathy and acute angle-closure glaucoma.The resulting ischemia can cause cell metabolic dysfunction,serious retinal damage and descending visual function.RIRI is the result of multiple factors.The currently accepted hypotheses mainly include the injury effect of oxygen-derived free radicals,intracellular calcium overload,the action of leucocyte and apoptosis.However the protection and treatment research in the RIRI is limited.The present paper reviews the progression in the drug intervention of RIRI.